Eisai Co., maker of the Alzheimer’s disease drug Aricept, said Japan’s Supreme Court ruled in its favor to extend a patent for the world’s best-selling treatment for the condition. Eisai’s patent is valid until June 22, 2013, after the court rejected an appeal by generic drugmakers, according to a faxed statement from the Japanese company today. To contact the reporter on this story: Go Onomitsu in Tokyo at gonomitsu@bloomberg.net
